达到的低密度脂蛋白胆固醇水平与长期心血管及安全性结局的关联:FOURIER-OLE分析
在FOURIER-OLE扩展研究中,6635例稳定动脉粥样硬化性心血管疾病患者转为开放标签依洛尤单抗治疗,中位随访5年。预设分析显示,达到的LDL-C水平越低(直至<20 mg/dL),主要疗效终点风险越低,且未观察到安全性结局风险显著增加。
要点
- LDL-C降至<20 mg/dL与主要疗效终点风险降低相关。
- 未发现更低LDL-C水平与严重不良事件等安全性风险增加相关。
- 长期随访至最大8.6年,结果与主分析一致。
核心结论
- 在动脉粥样硬化性心血管疾病患者中,长期达到较低LDL-C水平(直至<20 mg/dL)与心血管结局风险降低相关,且无显著安全性担忧。
研究设计与样本
- FOURIER-OLE为开放标签扩展研究,6635例患者从FOURIER随机试验转入开放标签依洛尤单抗治疗,中位额外随访5年。
- 本次预设分析纳入6559例有LDL-C测量值的患者,分析达到的LDL-C水平与后续心血管及安全性结局的关系。
主要发现
- 达到LDL-C<20、20至<40、40至<55、55至<70和≥70 mg/dL的患者分别有1604例(24%)、2627例(40%)、1031例(16%)、486例(7%)和811例(12%)。
- 达到的LDL-C水平越低(直至<20 mg/dL),主要疗效终点和关键次要疗效终点风险越低,多变量调整后趋势P<0.0001。
- 主要分析中,达到的LDL-C水平与安全性结局(严重不良事件、新发或复发癌症、白内障相关不良事件、出血性卒中、新发糖尿病、神经认知不良事件、肌肉相关事件或非心血管死亡)风险增加无统计学显著关联。
关键数值与推荐
- 主要疗效终点为心血管死亡、心肌梗死、卒中、不稳定心绞痛住院或冠状动脉血运重建的复合终点。
- 关键次要疗效终点为心血管死亡、心肌梗死或卒中的复合终点。
临床怎么用
- 对于动脉粥样硬化性心血管疾病患者,可考虑将LDL-C降至更低水平(直至<20 mg/dL)以降低心血管风险,无需担心所评估的安全性结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for atherosclerotic cardiovascular disease. However, the optimal achieved LDL-C level with regard to efficacy and safety in the long term remains unknown. METHODS: In FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk), 27 564 patients with stable atherosclerotic cardiovascular disease were randomized to evolocumab versus placebo, with a median follow-up of 2.2 years. In the open-label extension (FOURIER-OLE), 6635 of these patients were transitioned to open-label evolocumab regardless of initial treatment allocation in the parent trial and were followed for an additional median of 5 years. In this prespecified analysis, we examined the relationship between achieved LDL-C levels (an average of the first 2 LDL-C levels measured) in FOURIER-OLE (available in 6559 patients) and the incidence of subsequent cardiovascular and safety outcomes. We also performed sensitivity analyses evaluating cardiovascular and safety outcomes in the entire FOURIER and FOURIER-OLE patient population. Multivariable modeling was used to adjust for baseline factors associated with achieved LDL-C levels. RESULTS: In FOURIER-OLE, 1604 (24%), 2627 (40%), 1031 (16%), 486 (7%), and 811 (12%) patients achieved LDL-C levels of <20, 20 to <40, 40 to <55, 55 to <70, and ≥70 mg/dL, respectively. There was a monotonic relationship between lower achieved LDL-C levels-down to very low levels <20 mg/dL-and a lower risk of the primary efficacy end point (composite of cardiovascular death, myocardial infarction, stroke, hospital admission for unstable angina or coronary revascularization) and the key secondary efficacy end point (composite of cardiovascular death, myocardial infarction, or stroke) that persisted after multivariable adjustment (adjusted Ptrend<0.0001 for each end points). No statistically significant associations existed in the primary analyses between lower achieved LDL-C levels and increased risk of the safety outcomes (serious adverse events, new or recurrent cancer, cataract-related adverse events, hemorrhagic stroke, new-onset diabetes, neurocognitive adverse events, muscle-related events, or noncardiovascular death). Similar findings were noted in the entire FOURIER and FOURIER-OLE cohort up to a maximum follow-up of 8.6 years. CONCLUSIONS: In patients with atherosclerotic cardiovascular disease, long-term achievement of lower LDL-C levels, down to <20 mg/dL (<0.5 mmol/L), was associated with a lower risk of cardiovascular outcomes with no significant safety concerns. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01764633.
引用
- Gaba P, O'Donoghue ML, Park JG, et al. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. Circulation. 2023. PMID: 36779348. doi:10.1161/CIRCULATIONAHA.122.063399
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。